The effects of vasopressor choice on renal outcomes in septic shock: a systematic review of randomised trials as a guide for future research - Scorecard - MDSpire
Advertisement
The effects of vasopressor choice on renal outcomes in septic shock: a systematic review of randomised trials as a guide for future research
Clinical Scorecard: Impact of Vasopressor Selection on Kidney Outcomes in Septic Shock: A Systematic Review of Randomized Trials to Inform Future Investigations
At a Glance
Category
Detail
Condition
Septic shock with risk of acute kidney injury (AKI)
Key Mechanisms
Dysregulated host response to infection causing organ dysfunction; vasopressors used to maintain blood pressure may affect renal perfusion and injury
Target Population
Adult patients (≥18 years) with septic shock requiring vasopressor therapy
Care Setting
Critical care units managing septic shock patients
Key Highlights
Septic shock patients have a high risk of AKI, which significantly increases mortality.
Current guidelines recommend norepinephrine as first-line vasopressor, adding vasopressin if needed, but evidence quality varies.
Renal outcomes have been underreported in vasopressor trials despite their clinical importance.
Guideline-Based Recommendations
Diagnosis
Septic shock defined by vasopressor requirement and elevated serum lactate per international consensus definitions.
Management
Use intravenous crystalloid resuscitation and norepinephrine to maintain mean arterial pressure targets.
Add vasopressin as a second agent if norepinephrine alone is insufficient.
Monitoring & Follow-up
Monitor for development of AKI using KDIGO, AKIN, or RIFLE criteria.
Assess renal outcomes including AKI incidence, duration, renal replacement therapy (RRT) use, and major adverse kidney events (MAKE) at 30 and 90 days.
Risks
AKI in septic shock increases mortality up to 70%.
Variation in vasopressor choice may impact renal perfusion and injury.
Patient & Prescribing Data
Adults with septic shock receiving vasopressors
Norepinephrine is recommended first-line; vasopressin may be added. Evidence quality for vasopressor impact on renal outcomes is moderate to low, highlighting need for further research.
Clinical Best Practices
Apply international consensus definitions for septic shock to identify eligible patients.
Prioritize norepinephrine as first-line vasopressor to maintain blood pressure.
Consider vasopressin as adjunctive therapy when norepinephrine is insufficient.
Closely monitor renal function using standardized AKI criteria and renal outcome measures.
Recognize the importance of tailoring vasopressor therapy to individual renal risk profiles.
Support further high-quality randomized trials focusing on renal outcomes in septic shock vasopressor therapy.
